Key result
In patients with acute decompensated heart failure, an in-hospital reduction in CA125 levels was associated with a lower rate of 30-day mortality or rehospitalization.
Why the study?
Many patients with acute decompensated heart failure are discharged with residual congestion, driving interest in biomarkers like CA125 as objective tools to guide decongestion therapy.
Does a reduction in CA125 levels during hospitalization correlate with improved clinical decongestion and reduced 30-day mortality or HF rehospitalization in patients with ADHF?
Cohort (n=213)
No
Does a reduction in CA125 levels during hospitalization correlate with improved clinical decongestion and reduced 30-day mortality or HF rehospitalization in patients with ADHF?
Answers are grounded in this paper and cite their sources.
In-hospital reduction of CA125 levels in ADHF patients is associated with better clinical decongestion and lower 30-day rates of mortality or HF rehospitalization.
Background: Acute decompensated heart failure (ADHF) is a major cause of morbidity and mortality, with congestion being the primary reason for hospitalization. Despite treatment, many patients are discharged with residual congestion, hence the growing interest in utilizing biomarkers as objective tools to guide decongestion therapy. Carbohydrate Antigen 125 (CA125) has emerged as a promising biomarker of systemic congestion, with potential advantages over routine markers. This study evaluated the relationship between CA125 changes and clinical congestion score (CCS) at discharge and assessed its association with 30-day outcomes. Methods: This was a prospective cohort study conducted over seven months at Moi Teaching and Referral Hospital, a tertiary hospital in Western Kenya. Patients with ADHF were enrolled. CA125 levels were measured at admission and discharge using an automated immunoassay. In addition, other markers of congestion, i.e., CCS, NT-proBNP levels, body weight, and inferior vena cava (IVC) diameter, were assessed at both admission and discharge. The 30-day outcomes, which included all-cause mortality and heart failure (HF) rehospitalizations, were recorded. Statistical analyses included correlation and generalized linear models. Patients with in-hospital CA125 reductions had lower rates of the composite 30-day outcome (all-cause mortality or HF rehospitalization) at 15%, compared to 40% in those with rising CA125 levels. Conclusion: A reduction in CA125 levels during hospitalization is associated with better clinical decongestion and improved short-term outcomes.
No takes yet. Share an insight, caveat, or question.
Abutika et al. (2026) conducted a cohort in Acute decompensated heart failure (ADHF) (n=213). In-hospital reduction in CA125 levels vs. In-hospital increase in CA125 levels was evaluated on Composite of 30-day all-cause mortality or heart failure rehospitalization. In patients with acute decompensated heart failure, an in-hospital reduction in CA125 levels was associated with a lower rate of 30-day mortality or rehospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: